After the initial EGFR studies in clinic and the success of cetuximab combinations (40, 93, 94), cetuximab in HNSCC and the role of EGFR amplification and expression have been disputed since then (95). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.